These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 11602419

  • 1. Delayed cytogenetic response with prolonged interferon-alpha treatment in chronic myeloid leukemia patients: quantification of BCR-ABL transcript by competitive reverse transcription-polymerase chain reaction.
    Perego RA, Nosari AM, Cornacchini G, Bianchi C, Corizzato M, Morra E.
    Haematologica; 2001 Oct; 86(10):1101-3. PubMed ID: 11602419
    [No Abstract] [Full Text] [Related]

  • 2. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
    Xing W, Gu BW, Zhu YM, Jiang CL, Zhao RH, Wang AH, Sun HP, Li JM, Shen ZX, Chen Z, Chen SJ.
    Zhonghua Yi Xue Za Zhi; 2005 Feb 23; 85(7):453-7. PubMed ID: 15854550
    [Abstract] [Full Text] [Related]

  • 3. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
    Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N.
    Haematologica; 2004 May 23; 89(5):611-3. PubMed ID: 15136228
    [Abstract] [Full Text] [Related]

  • 4. Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.
    Cariani E, Capucci M, Micheletti M, Spalenza F, Zanella I, Albertini A, Rossi G.
    Ann Hematol; 2003 Jun 23; 82(6):333-5. PubMed ID: 12734675
    [Abstract] [Full Text] [Related]

  • 5. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
    Alimena G, Breccia M, Luciano L, Quarantelli F, Diverio D, Izzo B, De Angelis B, Mancini M, Latagliata R, Carmosino I, Nanni M, Picardi M, Rotoli B, Mandelli F, Pane F.
    Leuk Res; 2008 Feb 23; 32(2):255-61. PubMed ID: 17692911
    [Abstract] [Full Text] [Related]

  • 6. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu, Turkina AG, Misiurin AV, Aksenova EV, Domracheva EV, Zakharova AV, Khoroshko ND.
    Ter Arkh; 2007 Feb 23; 79(4):49-53. PubMed ID: 17564019
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
    Breccia M, Diverio D, Pane F, Nanni M, Russo E, Biondo F, Frustaci A, Gentilini F, Alimena G.
    Leuk Res; 2006 Dec 23; 30(12):1577-9. PubMed ID: 16630657
    [Abstract] [Full Text] [Related]

  • 9. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
    Snyder DS, McMahon R, Cohen SR, Slovak ML.
    Am J Hematol; 2004 Feb 23; 75(2):92-5. PubMed ID: 14755375
    [Abstract] [Full Text] [Related]

  • 10. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B, Woroniecka R, Solarska I, Kos K, Pastwińska A, Konopka L, Majewski M.
    Cancer Genet Cytogenet; 2007 Apr 15; 174(2):111-5. PubMed ID: 17452251
    [Abstract] [Full Text] [Related]

  • 11. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH.
    Cancer; 2008 Aug 15; 113(4):772-81. PubMed ID: 18543309
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
    Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger MW.
    Haematologica; 2004 Jan 15; 89(1):49-57. PubMed ID: 14754606
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.
    Clin Cancer Res; 2005 May 01; 11(9):3425-32. PubMed ID: 15867244
    [Abstract] [Full Text] [Related]

  • 19. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
    Prejzner W.
    Med Sci Monit; 2002 May 01; 8(5):BR193-7. PubMed ID: 12011769
    [Abstract] [Full Text] [Related]

  • 20. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL, Tallman MS, Variakojis D, Druker BJ, Resta D, Riley MB, Hrisinko MA, Peterson LC.
    Am J Clin Pathol; 2003 Jun 01; 119(6):833-41. PubMed ID: 12817431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.